Acute myeloid leukemia (AML) is a type of blood and bone marrow cancer. AML can affect people of any age, but it is most common in adults. AML occurs when bone marrow produces abnormal blood cells, ...

Medications for AML include chemotherapy and newer targeted therapies. With several options available, the right medication for you will depend on the specific characteristics of your cancer. Acute ...

Despite advances in cancer treatment in recent years, five-year survival rates for acute myeloid leukemia (AML) remain low at just 30% on average, according to the National Cancer Institute. Factors ...

Scientists have refined and enhanced the classification system for a type of pediatric leukemia using genomic and transcriptomic analysis. Compared to adult cancers, pediatric cancers often have ...

US biotech major Amgen has announced its acquisition of privately-held UK firm Dark Blue Therapeutics, a biotech advancing ...

Preclinical AML studies showed palbociclib plus venetoclax produced stronger, more durable anti‑leukemia activity than venetoclax alone and may overcome resistance.

A breast cancer drug paired with venetoclax significantly enhanced leukemia cell killing and durability in preclinical tests.

The FINANCIAL — Novartis on September 20 announced that the European Commission (EC) approved Rydapt (midostaurin) for two indications in rare, hard-to-treat cancers. Rydapt is approved for use in ...